Direct transfer of p65 into T lymphocytes from systemic lupus erythematosus patients leads to increased levels of interleukin-2 promoter activity.
The recent identification of a number of molecular defects in T cells from patients with systemic lupus erythematosus (SLE) has raised expectations for gene replacement therapy as an option in the treatment of these diseases. In this report, we have adapted an electroporation-based technique to transfer successfully DNA to peripheral blood T cells from normal individuals and patients with systemic lupus erythematosus and rheumatoid arthritis. Transfection efficiency, judged by the percentage of live cells expressing green fluorescence after transfection with a pGFP (green fluorescence protein), reached 32 +/- 3% in normal, 13 +/- 3% in SLE, and 17 +/- 13% in RA T cells. The transfection efficiency was slightly higher in CD8+ than in CD4+ cells, and the cells maintained acceptable (75%) viability up to the fourth post-transfection day. SLE T cells have been shown to display low levels of the p65 subunit of the NF-kappaB transcription factor and decreased production of IL-2. Since NF-kappaB contributes to the transcriptional regulation of the IL-2 promoter, the effect of the forced replenishment of p65 on IL-2 transcription was tested. The low level of interleukin-2 promoter activity in SLE T cells increased to normal levels following transfection with cDNA encoding the NF-kappaB p65 subunit. Taken together, these results demonstrate the feasibility of transfection of T cells from SLE patients by electroporation and the reversal of decreased interleukin-2 promoter activity in SLE T cells, and are an early step toward gene therapy as a method of treatment for these individuals.
Herndon
Thomas M
TM
Department of Cellular Injury, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, USA.
Juang
Yuang-Taung
YT
Solomou
Elena E
EE
Rothwell
Stephen W
SW
Gourley
Mark F
MF
Tsokos
George C
GC
D001172:Arthritis, Rheumatoid / Q000235:genetics / Q000276:immunology / Q000378:metabolism / Q000628:therapy; D018076:DNA, Complementary / Q000235:genetics; D018274:Electroporation; D015870:Gene Expression; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D049452:Green Fluorescent Proteins; D006801:Humans; D066298:In Vitro Techniques; D007376:Interleukin-2 / Q000235:genetics* / Q000494:pharmacology; D008164:Luminescent Proteins / Q000235:genetics; D008180:Lupus Erythematosus, Systemic / Q000235:genetics* / Q000276:immunology* / Q000378:metabolism / Q000628:therapy; D016328:NF-kappa B / Q000235:genetics* / Q000378:metabolism; D010835:Phytohemagglutinins / Q000494:pharmacology; D011401:Promoter Regions, Genetic; D011994:Recombinant Proteins / Q000235:genetics; D013601:T-Lymphocytes / Q000276:immunology* / Q000378:metabolism; D051996:Transcription Factor RelA; D014162:Transfection
D018076:DNA, Complementary; D007376:Interleukin-2; D008164:Luminescent Proteins; D016328:NF-kappa B; D010835:Phytohemagglutinins; D011994:Recombinant Proteins; D051996:Transcription Factor RelA; D049452:Green Fluorescent Proteins